Changing what’s possible
for People living with T cell-driven autoimmune disease

DELIVERING siRNA, ONLY TO T CELLS

Selective delivery of siRNA to T cells enables modulation of the specific T cell sub-types that drive disease pathology with sequence-level specificity and greater pharmacologic control.

siRNA delivery to T cells has historically been limited by the inability to selectively target T cells, while maintaining efficient release of siRNA into the cytoplasm.

Delivering siRNA with our T cell specific cell-targeted lipid nanoparticle (ctLNP) could silence disease-driving genes in T cells with genetic precision, potently blocking their function while sparing the broader immune system.

THE POWER OF CHANGING T CELL BEHAVIOR IN VIVO

T cells are master regulators of the immune system, and they are at the heart of tissue damage in a number of autoimmune diseases. Autoreactive T cells have a role in breaking tolerance and directly drive inflammation and tissue destruction.

By changing the activity of T cells, our targets can change how T cells activate, differentiate, migrate, and damage tissues.

Using our redosable ctLNP delivery system to selectively target T cells in vivo may open a broad indication space of T cell-driven autoimmune diseases.

Our unique delivery unlocks T CELL access for siRNA therapeutics

Delivery of siRNA to T cells requires receptor-selective targeting and endosomal escape – our unique ctLNP delivery technology accomplishes both for the first time.

These features unlock a broad landscape of targets to address T cell-driven autoimmune diseases, including targets that have been impossible to drug with other modalities.

We are prioritizing T cell-driven autoimmune indications based on severity and unmet need, on achieving rapid clinical proof of concept with a clear clinical and regulatory pathway, and on the degree of differentiation for our approach.